Eli Lilly announced on Monday that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in a late-stage trial. The drugmaker plans to submit the results to the U.S. FDA by the end of the year to seek approval for treating moderate-to-severe obstructive sleep apnea